As Investors Retreat, Sequenom Loses Options. Will Firm Be Acquired Soon? | GenomeWeb

When Sequenom releases its second-quarter earnings Thursday morning, investors, customers, and collaborators will be looking to see whether the company can arrest a six-month slide in its stock price.

Though quarterly revenues have grown since the second period last year, receipts for the first three months of 2004 have fallen by $2.3 million year over year because of a challenging market for high-throughput genotyping systems.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.